Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MYRX
Previous Symbol
CUSIPN/A
Phone801-214-7800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares34,480,000
Market Cap$390,000.00
OptionableNot Optionable
Myrexis (OTCMKTS:MYRX) Frequently Asked Questions
What is Myrexis' stock symbol?
Myrexis trades on the OTCMKTS under the ticker symbol "MYRX."
Has Myrexis been receiving favorable news coverage?
News headlines about MYRX stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Myrexis earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Myrexis' key competitors?
Some companies that are related to Myrexis include Aoxing Pharmaceutical (AOXG), RXi Pharmaceuticals (RXII), GlobeImmune (GBIM), Cotinga Pharmaceuticals (COTQF), Affymax (AFFY), FutureWorld (FWDG), Tetralogic Pharmaceuticals (TLOG), Spotlight Innovation (STLT), Targeted Medical Pharma (TRGM), Aeolus Pharmaceuticals (AOLS), HST Global (HSTC), American Oriental Bioengineering (AOBI), Orexigen Therapeutics (OREXQ), Pivotal Therapeutics (PVTTF) and Poniard Pharmaceuticals (PARD).
Who are Myrexis' key executives?
Myrexis' management team includes the folowing people:
- Mr. Jonathan M. Couchman, Chairman, CEO, Pres, CFO and Principal Accounting Officer (Age 48)
How do I buy shares of Myrexis?
Shares of MYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myrexis' stock price today?
One share of MYRX stock can currently be purchased for approximately $0.0114.
How big of a company is Myrexis?
Myrexis has a market capitalization of $390,000.00.
What is Myrexis' official website?
How can I contact Myrexis?
Myrexis' mailing address is C/O XSTELOS HOLDINGS INC. 630 FIFTH AVENUE SUITE 2260, NEW YORK NY, 10020. The biopharmaceutical company can be reached via phone at 801-214-7800 or via email at [email protected]
MarketBeat Community Rating for Myrexis (OTCMKTS MYRX)
MarketBeat's community ratings are surveys of what our community members think about Myrexis and other stocks. Vote "Outperform" if you believe MYRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
